Structural and metabolic consequences of liposome-lipoprotein interactions

Advanced Drug Delivery Reviews

Volumn 32, Issue 1-2, 1998, Pages 31-43

  Rodrigueza, Wendi V ^a   Phillips, Michael C ^a   Williams, Kevin Jon ^a,b  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Apolipoproteins; Atherosclerosis; Lipoproteins; Liposomes

Indexed keywords

BIOLOGICAL MEMBRANES; DRUG DOSAGE; DRUG INTERACTIONS; METABOLISM; PROTEINS;

ATHEROSCLEROSIS; LIPOPROTEINS; LIPOSOMES;

CONTROLLED DRUG DELIVERY;

APOLIPOPROTEIN; HIGH DENSITY LIPOPROTEIN; LIPOSOME; PHOSPHATIDYLCHOLINE;

ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; ENCAPSULATION; LIPID BILAYER; LIPOPROTEIN METABOLISM; MEMBRANE STRUCTURE; MEMBRANE TRANSPORT; PRIORITY JOURNAL; PROTEIN STABILITY; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0032496712     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(97)00130-0     Document Type: Review

References (120)

1. Bangham A. Membrane models with phospholipids. Prog. Biophys. Mol. Biol. 18:1968;89-95.
2. Williams K.J., Werth V.P., Wolff J.A. Intravenously administered lecithin liposomes: a synthetic antiatherogenic lipid particle. Perspect. Biol. Med. 27:1984;417-431.
3. Friedman M., Byers S.O., Rosenman R.H. Resolution of aortic atherosclerotic infiltration in the rabbit by phosphatide infusion. Proc. Soc. Exp. Biol. Med. 95:1957;586-588.
4. Tall A.R., Tabas I., Williams K.J. Lipoprotein-liposome interactions. Methods Enzymol. 128:1986;647-657.
5. K.J. Williams, A.R. Tall, Interactions of liposomes with lipoproteins: relevance to drug delivery systems and to the treatment of atherosclerosis, in: G. Gregoriadis (Ed.), Liposomes as Drug Carriers, Wiley, New York, 1988, pp. 93-111.
6. H.J. Pownall, J.B. Massey, J.T. Sparrow, A.M. Gotto Jr., Lipid-protein interactions and lipoprotein reassembly, in: A.M.J. Gotto (Ed.), Plasma Lipoproteins, Elsevier, New York, 1987, pp. 95-127.
7. A. Jonas, Lipid-binding properties of apolipoproteins, in: M. Rosseneu (Ed.), Structure and Function of Apolipoproteins, CRC Press, Boca Raton, FL, 1992, pp. 217-250.
8. Jian B., de la Llera-Moya M., Royer L., Rothblat G., Francone O.L., Swaney J.B. Modification of the cholesterol efflux properties of human serum by enrichment with phospholipid. J. Lipid Res. 38:1997;734-744.
9. Williams K.J., Scanu A.M. Uptake of endogenous cholesterol by a synthetic lipoprotein. Biochim. Biophys. Acta. 875:1986;183-194.
10. Scherphof G., Roerdink F., Waite M., Parks J. Disintegration of phosphatidylcholine liposomes in plasma as a result of interaction with high-density lipoproteins. Biochim. Biophys. Acta. 542:1978;296-307.
11. Scherphof G., Morselt H. On the size-dependent disintegration of small unilamellar phosphatidylcholine vesicles in rat plasma. Evidence of complete loss of vesicle structure. Biochem. J. 221:1984;423-429.
12. Huuskonen J., Olkkonen V.M., Jauhiainen M., Metso J., Somerharju P., Ehnholm C. Acyl chain and headgroup specificity of human plasma phospholipid transfer protein. Biochim. Biophys. Acta. 1303:1996;207-214.
13. Lusa S., Jauhiainen M., Metso J., Somerharju P., Ehnholm C. The mechanism of human plasma phopsholipid transfer protein-induced enlargement of high density lipoprotein particles: evidence for particle fusion. Biochem. J. 313:1996;275-282.
14. Mendez A.J., He J.L., Huang H.S., Wen S.R., Hsia S.L. Interaction of rabbit lipoproteins and red blood cells with liposomes of egg yolk phospholipids. Lipids. 23:1988;961-967.
15. Brouillette C.G., Anantharamaiah G.M. Structural models of human apolipoprotein A-I. Biochim. Biophys. Acta. 1256:1995;103-129.
16. Jonas A. A review of plasma apolipoprotein A-I interactions with phosphatidylcholines. Exp. Lung Res. 6:1984;255-270.
17. Yokoyama S., Fukushima D., Kupferberg J.P., Kezdy F.J., Kaiser E.T. The mechanism of activation of lecithin:cholesterol acyltransferase by apolipoprotein A-I and an amphiphilic peptide. J. Biol. Chem. 255:1980;7333-7339.
18. Mui B.L., Cullis P.R., Pritchard P.H., Madden T.D. Influence of plasma on the osmotic sensitivity of large unilamellar vesicles prepared by extrusion. J. Biol. Chem. 269:1994;7364-7370.
19. Rodrigueza W.V., Williams K.J., Rothblat G.H., Phillips M.C. Remodeling and shuttling: mechanisms for synergistic effects between different acceptor particles in the mobilization of cellular cholesterol. Arterioscler. Thromb. Vasc. Biol. 17:1997;383-393.
20. Rodrigueza W.V., Mazany K.D., Essenburg A.D., Pape M.E., Rea T.J., Bisgaier C.L., Williams K.J. Large versus small unilamellar vesicles mediate reverse cholesterol transport in vivo into two distinct hepatic metabolic pools: implications for the treatment of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 17:1997;2132-2139.
21. Zakharova T.S., Ivanov A.S., Echkalov A.P., Beriozov A.T., Khalilov E.M., Archakov A.I. Interaction of cholesterol containing liposomes with blood serum lipoproteins. Biochem. Mol. Biol. Int. 31:1993;315-324.
22. Shahrokh Z., Nichols A.V. Interaction of human-plasma low-density lipoproteins with discoidal complexes of apolipoprotein A-I and phosphatidylcholine, and characterization of the interaction products. Biochim. Biophys. Acta. 837:1985;296-304.
23. McCloskey H.M., Rothblat G.H., Glick J.M. Incubation of acetylated low-density lipoprotein with cholesterol-rich dispersions enhances cholesterol uptake by macrophages. Biochim. Biophys. Acta. 921:1987;320-332.
24. M.C. Phillips, Interactions of apolipoproteins at interfaces, in: M. Rosseneu (Ed.), Structure and Function of Apolipoproteins, CRC Press, Boca Raton, FL, 1992, pp. 185-216.
25. Saito H., Miyako Y., Handa T., Miyajima K. Effect of cholesterol on apolipoprotein A-I binding to lipid bilayers and emulsions. J. Lipid Res. 38:1997;287-294.
26. Bonte F., Juliano R.L. Interactions of liposomes with serum proteins. Chem. Phys. Lipids. 40:1986;359-372.
27. Moghimi S.M., Patel H.M. Differential properties of organ-specific serum opsonins for liver and spleen macrophages. Biochim. Biophys. Acta. 984:1989;379-383.
28. Patel H.M. Serum opsonins and liposomes: their interaction and opsonophagocytosis. Crit. Rev. Ther. Drug Carrier Syst. 9:1992;39-90.
29. Oja C.D., Semple S.C., Chonn A., Cullis P.R. Influence of dose on liposome clearance: critical role of blood proteins. Biochim. Biophys. Acta. 1281:1996;31-37.
30. Kao Y.J., Juliano R.L. Interactions of liposomes with the reticuloendothelial system. Effects of reticuloendothelial blockade on the clearance of large unilamellar vesicles. Biochim. Biophys. Acta. 677:1981;453-461.
31. Harashima H., Kume Y., Yamane C., Kiwada H. Non-Michaelis-Menten type hepatic uptake of liposomes in the rat. J. Pharm. Pharmacol. 44:1992;707-712.
32. Allen T.M., Hansen C. Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim. Biophys. Acta. 1068:1991;133-141.
33. Ogiwara M. Clearance and maximum removal rate of liposomes in normal and impaired liver of rat. Gastroenterol. Jpn. 19:1984;34-40.
34. Chonn A., Semple S.C., Cullis P.R. Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes. J. Biol. Chem. 267:1992;18759-18765.
35. Semple S.C., Chonn A., Cullis P.R. Influence of cholesterol on the association of plasma proteins with liposomes. Biochemistry. 35:1996;2521-2525.
36. Liu D., Song Y.K., Liu F. Antibody dependent, complement-mediated liver uptake of liposomes containing GM1. Pharm. Res. 12:1995;1775-1780.
37. Funato K., Yamashita C., Kamada J., Tominaga S., Kiwada H. Plasma factor triggering alternative complement pathway activation by liposomes. Pharm. Res. 11:1994;372-376.
38. Devine D.V., Wong K., Serrano K., Chonn A., Cullis P.R. Liposome-complement interactions in rat serum: implications for liposome survival studies. Biochim. Biophys. Acta. 1191:1994;43-51.
39. Moghimi S.M., Patel H.M. Serum factors that regulate phagocytosis of liposomes by Kupffer cells. Biochem. Soc. Trans. 21:1993;128S.
40. Lee K.D., Hong K., Papahadjopoulos D. Recognition of liposomes by cells: in vitro binding and endocytosis mediated by specific lipid headgroups and surface charge density. Biochim. Biophys. Acta. 1103:1992;185-197.
41. Nishikawa K., Arai H., Inoue K. Scavenger receptor-mediated uptake and metabolism of lipid vesicles containing acidic phospholipids by mouse peritoneal macrophages. J. Biol. Chem. 265:1990;5226-5231.
42. Greenspan P. Phosphatidylserine-mediated delivery of cholesterol to macrophages: a novel experimental method for the generation of foam cells. Biochim. Biophys. Acta. 1045:1990;94-96.
43. Liu F., Liu D. Serum independent liposome uptake by mouse liver. Biochim. Biophys. Acta. 1278:1996;5-11.
44. Allen T.M., Hansen C., Rutledge J. Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues. Biochim. Biophys. Acta. 981:1989;27-35.
45. Williams K.J., Tall A.R., Tabas I., Blum C. Recognition of vesicular lipoproteins by the apolipoprotein B,E receptor of cultured fibroblasts. J. Lipid Res. 27:1986;892-900.
46. Williams K.J., Tall A.R., Bisgaier C., Brocia R. Phospholipid liposomes acquire apolipoprotein E in atherogenic plasma and block cholesterol loading of cultured macrophages. J. Clin. Invest. 79:1987;1466-1472.
47. Angelin B., Raviola C.A., Innerarity T.L., Mahley R.W. Regulation of hepatic lipoprotein receptors in the dog. Rapid regulation of apolipoprotein B,E receptors, but not of apolipoprotein E receptors, by intestinal lipoproteins and bile acids. J. Clin. Invest. 71:1983;816-831.
48. Mahley R.W., Hui D.Y., Innerarity T.L., Beisiegel U. Chylomicron remnant metabolism. Role of hepatic lipoprotein receptors in mediating uptake. Arteriosclerosis. 9(Suppl I):1989;14-18.
49. Beisiegel U., Weber W., Ihrke G., Herz J., Stanley K.K. The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein. Nature. 341:1989;162-164.
50. Williams K.J., Vallabhajosula S., Rahman I.U., Donnelly T.M., Parker T.S., Weinrauch M., Goldsmith S.J. Low density lipoprotein receptor-independent hepatic uptake of a synthetic, cholesterol-scavenging lipoprotein: implications for the treatment of receptor-deficient atherosclerosis. Proc. Natl. Acad. Sci. USA. 85:1988;242-246.
51. Bisgaier C.L., Siebenkas M.V., Williams K.J. Effects of apolipoproteins A-IV and A-I on the uptake of phospholipid liposomes by hepatocytes. J. Biol. Chem. 264:1989;862-866.
52. Claypool W.D., Wang D.L., Chander A., Fisher A.B. "Hydrophobic" surfactant apoproteins and augmentation of phospholipid recycling. Exp. Lung Res. 6:1984;215-222.
53. Chonn A., Semple S.C., Cullis P.R. Beta 2 glycoprotein I is a major protein associated with very rapidly cleared liposomes in vivo, suggesting a significant role in the immune clearance of "non-self" particles. J. Biol. Chem. 270:1995;25845-25849.
54. Rodrigueza W.V., Pritchard P.H., Hope M.J. The influence of size and composition on the cholesterol mobilizing properties of liposomes in vivo. Biochim. Biophys. Acta. 1153:1993;9-19.
55. Schroit A.J., Fidler I.J. Effects of liposome structure and lipid composition on the activation of the tumoricidal properties of macrophages by liposomes containing muramyl dipeptide. Cancer Res. 42:1982;161-167.
56. Allen T.M., Williamson P., Schlegel R.A. Phosphatidylserine as a determinant of reticuloendothelial recognition of liposome models of the erythrocyte surface. Proc. Natl. Acad. Sci. USA. 85:1988;8067-8071.
57. Kodama T., Freeman M., Rohrer L., Zabrecky J., Matsudaira P., Krieger M. Type I macrophage scavenger receptor contains alpha-helical and collagen-like coiled coils. Nature. 343:1990;531-535.
58. Sparrow C.P., Parthasarathy S., Steinberg D. A macrophage receptor that recognizes oxidized low density lipoprotein but not acetylated low density lipoprotein. J. Biol. Chem. 264:1989;2599-2604.
59. Miyazaki A., Sakai M., Suginohara Y., Hakamata H., Sakamoto Y., Morikawa W., Horiuchi S. Acetylated low density lipoprotein reduces its ligand activity for the scavenger receptor after interaction with reconstituted high density lipoprotein. J. Biol. Chem. 269:1994;5264-5269.
60. Lee K.D., Pitas R.E., Papahadjopoulos D. Evidence that the scavenger receptor is not involved in the uptake of negatively charged liposomes by cells. Biochim. Biophys. Acta. 1111:1992;1-6.
61. Acton S.L., Scherer P.E., Lodish H.F., Krieger M. Expression cloning of SR-BI, a CD36-related class B scavenger receptor. J. Biol. Chem. 269:1994;21003-21009.
62. Rigotti A., Acton S.L., Krieger M. The class B scavenger receptors SR-BI and CD36 are receptors for anionic phospholipids. J. Biol. Chem. 270:1995;16221-16224.
63. Acton S., Rigotti A., Landschulz K.T., Xu S., Hobbs H.H., Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science. 271:1996;518-520.
64. Endemann G., Stanton L.W., Madden K.S., Bryant C.M., White R.T., Protter A.A. CD36 is a receptor for oxidized low density lipoprotein. J. Biol. Chem. 268:1993;11811-11816.
65. Landschulz K.T., Pathak R.K., Rigotti A., Krieger M., Hobbs H.H. Regulation of scavenger receptor, class B, type I, a high density lipoprotein receptor, in liver and steroidogenic tissues of the rat. J. Clin. Invest. 98:1996;984-995.
66. Constantinides P. Cause of thrombosis in human atherosclerotic arteries. Am. J. Cardiol. 66:1990;37G-40G.
67. Falk E. Why do plaques rupture? Circulation. 86(Suppl III):1992;30-42.
68. Davies M.J., Richardson P.D., Woolf N., Katz D.R., Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br. Heart J. 69:1993;377-381.
69. Brown B.G., Zhao X.Q., Sacco D.E., Albers J.J. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 87:1993;1781-1791.
70. Rodrigueza W.V., Mazany K.D., Essenburg A.D., Bisgaier C.L., Williams K.J. Large versus small unilamellar vesicles mediate reverse cholesterol transport in vivo into two distinct hepatic metabolic pools: implications for the treatment of atherosclerosis. Circulation. 92:1995;1-556.
71. Sloop C.H., Dory L., Roheim P.S. Interstitial fluid lipoproteins. J. Lipid Res. 28:1987;225-237.
72. Reichl D. Lipoproteins of human peripheral lymph. Eur. Heart J. 11(Suppl E):1990;230-236.
73. Davidson W.S., Rodrigueza W.V., Lund-Katz S., Johnson W.J., Rothblat G.H., Phillips M.C. Effects of acceptor particle size on the efflux of cellular free cholesterol. J. Biol. Chem. 270:1995;17106-17113.
74. Atger V., de la Llera Moya M., Stoudt G.W., Rodrigueza W.V., Phillips M.C., Rothblat G.H. Cyclodextrins as catalysts for the removal of cholesterol from macrophage foam cells. J. Clin. Invest. 99:1997;773-778.
75. Chow D.D., Essien H.E., Padki M.M., Hwang K.J. Targeting small unilamellar liposomes to hepatic parenchymal cells by dose effect. J. Pharmacol. Exp. Ther. 248:1989;506-513.
76. Roerdink F., Dijkstra J., Hartman G., Bolscher B., Scherphof G. The involvement of parenchymal, Kupffer and endothelial liver cells in the hepatic uptake of intravenously injected liposomes. Effects of lanthanum and gadolinium salts. Biochim. Biophys. Acta. 677:1981;79-89.
77. Spady D.K., Turley S.D., Dietschy J.M. Rates of low density lipoprotein uptake and cholesterol synthesis are regulated independently in the liver. J. Lipid Res. 26:1985;465-472.
78. Williams K.J., Brocia R.W., Fisher E.A. The unstirred water layer as a site of control of apolipoprotein B secretion. J. Biol. Chem. 265:1990;16741-16744.
79. Krause B.R., Pape M.E., Kieft K., Auerbach B., Bisgaier C.L., Homan R., Newton R.S. ACAT inhibition decreases LDL cholesterol in rabbits fed a cholesterol-free diet. Marked changes in LDL cholesterol without changes in LDL receptor mRNA abundance. Arterioscler. Thromb. 14:1994;598-604.
80. Stone B.G., Schreiber D., Alleman L.D., Ho C.Y. Hepatic metabolism and secretion of a cholesterol-enriched lipoprotein fraction. J. Lipid Res. 28:1987;162-172.
81. Kuivenhoven J.A., Demacker P.N.M., Stalenhoef A.F.H., Parjkrt D., van Deventer S.J.H., Doroan J.E., Pritchard P.H., Kastelein J.J.P. Infusion of reconstituted HDL: reverse cholesterol transport in hereditary HDL deficiencies. Circulation. 94(I):1996;343-344.
82. Thompson G.R., Jadhav A., Nava M., Gotto A.M. Jr. Effects of intravenous phospholipid on low density lipoprotein turnover in man. Eur. J. Clin. Invest. 6:1976;241-248.
83. Papahadjopoulos D., Allen T.M., Gabizon A., Mayhew E., Matthay K., Huang S.K., Lee K.D., Woodle M.C., Lasic D.D., Redemann C., Martin F.J. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. USA. 88:1991;11460-11464.
84. Chonn A., Cullis P.R. Recent advances in liposomal drug-delivery systems. Curr. Opin. Biotechnol. 6:1995;698-708.
85. Moghimi S.M., Patel H.M. Serum opsonins and phagocytosis of saturated and unsaturated phospholipid liposomes. Biochim. Biophys. Acta. 984:1989;384-387.
86. Damen J., Regts J., Scherphof G. Transfer and exchange of phospholipid between small unilamellar liposomes and rat plasma high density lipoproteins. Dependence on cholesterol content and phospholipid composition. Biochim. Biophys. Acta. 665:1981;538-545.
87. Davis C., Gregoriadis G. The effect of lipid composition on the stability of liposomes in vivo. Biochem. Soc. Trans. 7:1979;680-682.
88. Allen T.M., Chonn A. Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS Lett. 223:1987;42-46.
89. Larrabee A.L. Time-dependent changes in the size distribution of distearoylphosphatidylcholine vesicles. Biochemistry. 18:1979;3321-3326.
90. Nayar R., Hope M.J., Cullis P.R. Generation of large unilamellar vesicles from long-chain saturated phosphatidylcholines by extrusion techniques. Biochim. Biophys. Acta. 986:1989;200-206.
91. Yechiel E., Henis Y.I., Barenholz Y. Aging of rat heart fibroblasts: relationship between lipid composition, membrane organization and biological properties. Biochim. Biophys. Acta. 859:1986;95-104.
92. Slife C.W., Wang E., Hunter R., Wang S., Burgess C., Liotta D.C., Merrill A.H. Jr. Free sphingosine formation from endogenous substrates by a liver plasma membrane system with a divalent cation dependence and a neutral pH optimum. J. Biol. Chem. 264:1989;10371-10377.
93. Mathias S., Dressler K.A., Kolesnick R.N. Characterization of a ceramide-activated protein kinase: stimulation by tumor necrosis factor alpha. Proc. Natl. Acad. Sci. USA. 88:1991;10009-10013.
94. Harmala A.S., Porn M.I., Slotte J.P. Sphingosine inhibits sphingomyelinase-induced cholesteryl ester formation in cultured fibroblasts. Biochim. Biophys. Acta. 1210:1993;97-104.
95. Schissel S.L., Tweedie-Hardman J., Rapp J.H., Graham G., Williams K.J., Tabas I. Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein. Proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins. J. Clin. Invest. 98:1996;1455-1464.
96. Williams K.J., Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler. Thromb. Vasc. Biol. 15:1995;551-561.
97. Woodle M.C., Lasic D.D. Sterically stabilized liposomes. Biochim. Biophys. Acta. 1113:1992;171-199.
98. Woodle M.C., Newman M.S., Cohen J.A. Sterically stabilized liposomes: physical and biological properties. J. Drug Target. 2:1994;397-403.
99. Allen T.M., Newman M.S., Woodle M.C., Mayhew E., Uster P.S. Pharmacokinetics and anti-tumor activity of vincristine encapsulated in sterically stabilized liposomes. Int. J. Cancer. 62:1995;199-204.
100. Woodle M.C. Surface-modified liposomes: assessment and characterization for increased stability and prolonged blood circulation. Chem. Phys. Lipids. 64:1993;249-262.
101. Parr M.J., Ansell S.M., Choi L.S., Cullis P.R. Factors influencing the retention and chemical stability of poly(ethylene glycol)-lipid conjugates incorporated into large unilamellar vesicles. Biochim. Biophys. Acta. 1195:1994;21-30.
102. Woodle M.C., Engbers C.M., Zalipsky S. New amphipatic polymer-lipid conjugates forming long-circulating reticuloendothelial system-evading liposomes. Bioconjug. Chem. 5:1994;493-496.
103. Zalipsky S., Brandeis E., Newman M.S., Woodle M.C. Long circulating, cationic liposomes containing amino-PEG-phosphatidylethanolamine. FEBS Lett. 353:1994;71-74.
104. Allen T.M., Hansen C., Martin F., Redemann C., Yau-Young A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim. Biophys. Acta. 1066:1991;29-36.
105. Senior J., Delgado C., Fisher D., Tilcock C., Gregoriadis G. Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethylene glycol)-coated vesicles. Biochim. Biophys. Acta. 1062:1991;77-82.
106. Woodle M.C., Matthay K.K., Newman M.S., Hidayat J.E., Collins L.R., Redemann C., Martin F.J., Papahadjopoulos D. Versatility in lipid compositions showing prolonged circulation with sterically stabilized liposomes. Biochim. Biophys. Acta. 1105:1992;193-200.
107. Abra R.M., Hunt C.A. Liposome disposition in vivo. III. Dose and vesicle-size effects. Biochim. Biophys. Acta. 666:1981;493-503.
108. Borchard G., Kreuter J. Interaction of serum components with poly(methylmethacrylate) nanoparticles and the resulting body distribution after intravenous injection in rats. J. Drug Target. 1:1993;15-19.
109. Kreuter J. Drug targeting with nanoparticles. Eur. J. Drug Metab. Pharmacokinet. 19:1994;253-256.
110. Bally M.B., Nayar R., Masin D., Hope M.J., Cullis P.R., Mayer L.D. Liposomes with entrapped doxorubicin exhibit extended blood residence times. Biochim. Biophys. Acta. 1023:1990;133-139.
111. Parr M.J., Bally M.B., Cullis P.R. The presence of GM1 in liposomes with entrapped doxorubicin does not prevent RES blockade. Biochim. Biophys. Acta. 1168:1993;249-252.
112. Abra R.M., Hunt C.A. Liposome disposition in vivo IV: the interaction of sequential doses of liposomes having different diameters. Res. Commun. Chem. Pathol. Pharmacol. 36:1982;17-31.
113. Kadowaki S., Sugimoto K., Tsurumaki Y., Tabata Y., Ikada Y., Fujita J., Mori K.J. Application of poly(L-lactic acid) particles for the suppression of genetic resistance to bone marrow allografts by reticuloendothelial system-blockade. Biomed. Pharmacother. 47:1993;385-391.
114. Breslow J.L. Mouse models of atherosclerosis. Science. 272:1996;685-688.
115. Barnum S.R., Jones J.L., Mullerladner U., Samimi A., Campbell I.L. Chronic complement C3 gene expression in the CNS of transgenic mice with astrocyte-targeted interleukin-6 expression. GLIA. 18:1996;107-117.
116. Williams K.J., Fless G.M., Petrie K.A., Snyder M.L., Brocia R.W., Swenson T.L. Mechanisms by which lipoprotein lipase alters cellular metabolism of lipoprotein(a), low density lipoprotein, and nascent lipoproteins. Roles for low density lipoprotein receptors and heparan sulfate proteoglycans. J. Biol. Chem. 267:1992;13284-13292.
117. Fuki I.V., Kuhn K.M., Lomazov I.R., Rothman V.L., Tuszynski G.P., Iozzo R.V., Swenson T.L., Fisher E.A., Williams K.J. The syndecan family of proteoglycans. Novel receptors mediating internalization of atherogenic lipoproteins in vitro. J. Clin. Invest. 100:1997;1611-1622.
118. Piedrahita J.A., Zhang S.H., Hagaman J.R., Oliver P.M., Maeda N. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc. Natl. Acad. Sci. USA. 89:1992;4471-4475.
119. Plump A.S., Smith J.D., Hayek T., Aalto-Setala K., Walsh A., Verstuyft J.G., Rubin E.M., Breslow J.L. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 71:1992;343-353.
120. Rodrigueza W.V., Klimuk S.K., Pritchard P.H., Hope M.J. Cholesterol mobilization and regression of atheroma in cholesterol-fed rabbits induced by large unilamellar vesicles. Biochim. Biophys. Acta. 1368:1998;306-320.